bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2024-69-1-66-78bloodjour-517Research ArticleОБЗОРЫREVIEWSСиндром острого лизиса опухоли — актуальная мультидисциплинарная проблема детской онкогематологииAcute tumor lysis syndrome — an urgent multidisciplinary problem in pediatric hematologyhttps://orcid.org/0000-0001-7805-5616МатинянН. В.MatinyanN. V.

Матинян Нуне Вануниевна, доктор медицинских наук, заведующая отделом анестезиологии и реанимации НИИ детской онкологии и гематологии; профессор кафедры детской анестезиологии и интенсивной терапии

115522, Москва

117997, Moсква

Nune V. Matinyan, Dr. Sci. (Med.), Head of the Department of anesthesiology and reanimation; Professor of the Department of Pediatric anesthesiology and intensive care 

115522, Moscow

117997, Moscow

 

n.matinyan@ronc.ruhttps://orcid.org/0000-0001-9602-3052БелоусоваЕ. И.BelousovaE. I.

Белоусова Екатерина Игоревна, кандидат медицинских наук, анестезиолог-реаниматолог отдела анестезиологии и реанимации НИИ детской онкологии и гематологии

115522, Москва

Ekaterina I. Belousova, Cand. Sci. (Med.), intensivist of the Department of anesthesiology and reanimation 

115522, Moscow

moyra_526@mail.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

Валиев Тимур Теймуразович, доктор медицинских наук, заведующий отделением детской онкологии и гематологии (химиотерапии гемобластозов) № 1

115522, Москва

Timur T. Valiev, Dr. Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No.1 

115522, Moscow

timurvaliev@mail.ruНИИ детской онкологии и гематологии ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации; ФГБОУ «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPediatric Oncology and Hematology Research Institute, Blokhin Russian Cancer Research Center of the Ministry of Health of Russia; Pirogov Russian National Research Medical University of the Ministry of Health of RussiaRussian FederationНИИ детской онкологии и гематологии ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской ФедерацииРоссияPediatric Oncology and Hematology Research Institute, Blokhin Russian Cancer Research Center of the Ministry of Health of RussiaRussian Federation2024190320246916678Copyright © Матинян Н.В., Белоусова Е.И., Валиев Т.Т., 20242024Матинян Н.В., Белоусова Е.И., Валиев Т.Т.Matinyan N.V., Belousova E.I., Valiev T.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/517Введение

Введение. Синдром острого лизиса опухоли (СОЛО) является жизнеугрожающим осложнением терапии у детей с высокоагрессивными неходжкинскими лимфомами (III–IV стадии) и острыми лейкозами, протекающими с гиперлейкоцитозом свыше 100×10 9/л.

Цель — обзор литературы, посвященной диагностике, профилактике и лечению СОЛО у детей с опухолевыми заболеваниями системы крови.

Основные сведения

Основные сведения. Проведен поиск данных в медицинских информационных системах PubMed, ResearchGate и Elibrary с использованием ключевых слов «синдром лизиса опухоли», «синдром острого лизиса опухоли», «злокачественные лимфопролиферативные заболевания у детей» и «злокачественные новообразования у детей», ограничения поиска — клинические исследования, оригинальные статьи и литературные обзоры по изучаемому вопросу для лиц от рождения до 18 лет. Критериям поиска удовлетворяли 24 клинических исследования и 38 обзоров. СОЛО характеризовался острыми электролитными и метаболическими нарушениями, при отсутствии терапии приводил к полиорганной недостаточности и летальному исходу. Для успешного лечения необходимо раннее выявление факторов риска развития СОЛО. Профилактика и лечение СОЛО включает проведение циторедуктивной предфазы, инфузионной терапии, назначение аллопуринола и/или расбуриказы, при неэффективности консервативной терапии проводят гемодиафильтрацию.

Introduction

Introduction. Acute tumor lysis syndrome (ATLS) is a life-threatening complication of treatment in children with highly aggressive lymphomas (III–IV stages) and acute leukemias accompanied by hyperleukocytosis (above 100×109/L).

Aim

Aim. To conduct a literature review on the diagnosis, prevention and treatment of acute tumor lysis syndrome in pediatric diseases of the blood system.

Main findings

Main findings. Data was searched in PubMed, ResearchGate and Elibrary using the keywords tumor lysis syndrome, acute tumor lysis syndrome, malignant lymphoproliferative diseases in children and malignant neoplasms in children, limited to clinical trials, original articles and reviews on individuals from birth to 18 years of age. The search criteria were met by 24 clinical trials and 38 literature reviews. ATLS was characterized by acute electrolyte and metabolic disorders, and in the absence of therapy led to multiple organ failure and death. The prevention and treatment of ALTS includes cytoreductive prephase, infusion therapy, and/or allopurinol or rasburicase. If conservative therapy proves ineffective, hemodiafi ltration is performed.

   

синдром острого лизиса опухолилейкозылимфомызлокачественные новообразованияинтенсивная терапиягемодиафильтрациядетиacute tumor lysis syndromeleukemialymphomahyperleukocytosisintensive carehemodiafi ltrationchildrenReferencesMatuszkiewicz-Rowinska J., Malyszko J. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. Kidney Blood Press Res. 2020; 45(5): 645–60. DOI: 10.1159/000509934.Matuszkiewicz-Rowinska J., Malyszko J. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. Kidney Blood Press Res. 2020; 45(5): 645–60. DOI: 10.1159/000509934.Gangireddy M., Shrimanker I., Nookala V.K., Peroutka K.A. Spontaneous tumor lysis syndrome in diffuse largeB-cell lymphoma: early diagnosis and management. Cureus. 2019; 11(5): e4679.Gangireddy M., Shrimanker I., Nookala V.K., Peroutka K.A. Spontaneous tumor lysis syndrome in diffuse largeB-cell lymphoma: early diagnosis and management. Cureus. 2019; 11(5): e4679.Abdel-Nabey M., Chaba A., Serre J., et al. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. Ann Intensive Care. 2022; 12(1): 15. DOI: 10.1186/s13613-022-00990-1.Abdel-Nabey M., Chaba A., Serre J., et al. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. Ann Intensive Care. 2022; 12(1): 15. DOI: 10.1186/s13613-022-00990-1.Alakel N., Middeke J.M., Schetelig J., Bornhauser M. Prevention and treatment of tumor lysis syndrome, and the effi cacy and role of rasburicase. Onco Targets Ther. 2017; 10: 597–605.Alakel N., Middeke J.M., Schetelig J., Bornhauser M. Prevention and treatment of tumor lysis syndrome, and the effi cacy and role of rasburicase. Onco Targets Ther. 2017; 10: 597–605.Hande K.R., Garrow G.C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993; 94: 133–9. DOI: 10.1016/0002-9343(93)90174-N.Hande K.R., Garrow G.C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993; 94: 133–9. DOI: 10.1016/0002-9343(93)90174-N.Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classifi cation.Br J Haematol. 2004; 127: 311. DOI: 10.1111/j.13652141.2004.05094.x.Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classifi cation.Br J Haematol. 2004; 127: 311. DOI: 10.1111/j.13652141.2004.05094.x.Howard S.C., Jones D.P., Pui C.H. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54. DOI: 10.1056/NEJMra0904569.Howard S.C., Jones D.P., Pui C.H. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–54. DOI: 10.1056/NEJMra0904569.Xue Y., Chen J., Gao S., et al. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia. Sci Rep. 2021 May 6; 11(1): 9656. DOI: 10.1038/s41598-021-88912-2.Xue Y., Chen J., Gao S., et al. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia. Sci Rep. 2021 May 6; 11(1): 9656. DOI: 10.1038/s41598-021-88912-2.Baqari S.A, Haque A., Ashraf M.S., et al. Clinical profi le and short-term outcome of pediatric hyperleukocytic acute leukemia from a developing country. J Coll Physician Surg Pak. 2017; 27(7): 450–4.Baqari S.A, Haque A., Ashraf M.S., et al. Clinical profi le and short-term outcome of pediatric hyperleukocytic acute leukemia from a developing country. J Coll Physician Surg Pak. 2017; 27(7): 450–4.Khan M.I., Naseem L., Manzoor R., Yasmeen N. Mortality Analysis in Children during Induction Therapy for Acute Lymphoblastic Leukemia. JIMDC. 2017; 6(2): 69–72.Khan M.I., Naseem L., Manzoor R., Yasmeen N. Mortality Analysis in Children during Induction Therapy for Acute Lymphoblastic Leukemia. JIMDC. 2017; 6(2): 69–72.Bahoush G.R., Yazdi E., Ansari S.H., et al. Idenifi cation of children With Acute Lymphoblastic Leukemia at Low Risk for Tumor Lysis Syndrome. J Blood Disorder Transfus. 2015; 6: 318. DOI: 10.4172/2155-9864.1000318.Bahoush G.R., Yazdi E., Ansari S.H., et al. Idenifi cation of children With Acute Lymphoblastic Leukemia at Low Risk for Tumor Lysis Syndrome. J Blood Disorder Transfus. 2015; 6: 318. DOI: 10.4172/2155-9864.1000318.Saeed F., Vadsaria K., Siddiqui D.F., et al. Tumour Lysis Syndrome in children with hematological cancers: Experience at a tertiary care hospital in Karachi. J Pak Med Assoc. 2018; 68: 1625–30.Saeed F., Vadsaria K., Siddiqui D.F., et al. Tumour Lysis Syndrome in children with hematological cancers: Experience at a tertiary care hospital in Karachi. J Pak Med Assoc. 2018; 68: 1625–30.Dhar M., Prakash S., Pandey V., Pai V.K. Intraoperative tumor lysis syndrome in a child with Wilms’ tumor. Anesth Essays Res. 2016; 10(1): 145–7. DOI: 10.4103/0259-1162.171446.Dhar M., Prakash S., Pandey V., Pai V.K. Intraoperative tumor lysis syndrome in a child with Wilms’ tumor. Anesth Essays Res. 2016; 10(1): 145–7. DOI: 10.4103/0259-1162.171446.Cheung W.L., Hon K.L., Fung C.M., Leung A.K. Tumor lysis syndrome in childhood malignancies. Drugs Context. 2020; 9: 2019-8-2.Cheung W.L., Hon K.L., Fung C.M., Leung A.K. Tumor lysis syndrome in childhood malignancies. Drugs Context. 2020; 9: 2019-8-2.Howard S.C. Tumor lysis syndrome. N Engl J Med. 2011 May 12; 364(19): 1844–54. DOI: 10.1056/NEJMra0904569.Howard S.C. Tumor lysis syndrome. N Engl J Med. 2011 May 12; 364(19): 1844–54. DOI: 10.1056/NEJMra0904569.Locatelli F., Rossi F. Incidence and pathogenesis of tumor lysis syndrome. In: Ronco C, Rodeghiero, Eds. Hyperuricemic Syndromes: Pathophysiology and Therapy. Basel: KARGER; 2004. P. 61–8.Locatelli F., Rossi F. Incidence and pathogenesis of tumor lysis syndrome. In: Ronco C, Rodeghiero, Eds. Hyperuricemic Syndromes: Pathophysiology and Therapy. Basel: KARGER; 2004. P. 61–8.Durfee E.M., Tumor Lysis Syndrome. Crit Care Nurse. 2022; 42(3): 19–25.Durfee E.M., Tumor Lysis Syndrome. Crit Care Nurse. 2022; 42(3): 19–25.Tasmeen R., Islam A., Alam S.T., Begum M. Tumor Lysis Syndrome and Hyperleukocytosis in Childhood Acute Lymphoblastic Leukemia in a Tertiary Care Hospital. Mymensingh Med J. 2017; 26(4): 906–12.Tasmeen R., Islam A., Alam S.T., Begum M. Tumor Lysis Syndrome and Hyperleukocytosis in Childhood Acute Lymphoblastic Leukemia in a Tertiary Care Hospital. Mymensingh Med J. 2017; 26(4): 906–12.Arachchige D.T., McClure J. Electrolyte disorders in the critically ill Anaesth Intensive Care Med. 2020; 21(3): 147–53.Arachchige D.T., McClure J. Electrolyte disorders in the critically ill Anaesth Intensive Care Med. 2020; 21(3): 147–53.Meraz-Munoz A., Langote A., Jhaveri K., et al. Acute Kidney Injury in the Patient with Diagnostics. 2021; 11(4): 611. DOI: 10.3390/diagnostics11040611.Meraz-Munoz A., Langote A., Jhaveri K., et al. Acute Kidney Injury in the Patient with Diagnostics. 2021; 11(4): 611. DOI: 10.3390/diagnostics11040611.Gopakumar K.G., Seetharam S., Km J.K., et al. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting. Pediatr Blood Cancer. 2018; 65(12): e27401. DOI: 10.1002/pbc.27401.Gopakumar K.G., Seetharam S., Km J.K., et al. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting. Pediatr Blood Cancer. 2018; 65(12): e27401. DOI: 10.1002/pbc.27401.Najjari A., Shahbazmohammadi H., Omidinia E., Movafagh A.M. The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase. Asian Pac J Cancer Prev. 2021 Feb 1; 22(2): 627–32. DOI: 10.31557/APJCP.2021.22.2.627.Najjari A., Shahbazmohammadi H., Omidinia E., Movafagh A.M. The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase. Asian Pac J Cancer Prev. 2021 Feb 1; 22(2): 627–32. DOI: 10.31557/APJCP.2021.22.2.627.Kitchlu A., McArthur E., Amir E. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-based Cohort Study. JNCI J. Natl. Cancer Inst. 2019; 111: 727–36. DOI: 10.1093/jnci/djy167.Kitchlu A., McArthur E., Amir E. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-based Cohort Study. JNCI J. Natl. Cancer Inst. 2019; 111: 727–36. DOI: 10.1093/jnci/djy167.McCullough P.A., Beaver T.M., Bennett-Guerrero E., et al. Acute and chronic cardiovascular effects of hyperkalemia: New insights into prevention and clinical management. Rev Cardiovasc Med. 2014; 15(1): 11–23.McCullough P.A., Beaver T.M., Bennett-Guerrero E., et al. Acute and chronic cardiovascular effects of hyperkalemia: New insights into prevention and clinical management. Rev Cardiovasc Med. 2014; 15(1): 11–23.Burns, R.A., Topoz I., Reynolds S.L. Tumor lysis syndrome: risk factors, diagnosis, and management. Pediatr. Emerg. Care. 2014; 30(8): 571–6.Burns, R.A., Topoz I., Reynolds S.L. Tumor lysis syndrome: risk factors, diagnosis, and management. Pediatr. Emerg. Care. 2014; 30(8): 571–6.Kidney Disease Improving Global Outcomes KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012; 2: 1–138.Kidney Disease Improving Global Outcomes KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012; 2: 1–138.Darmon M., Vincent F., Camous L., et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique. Br. J. Haematol. 2013; 162(4): 489–97.Darmon M., Vincent F., Camous L., et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique. Br. J. Haematol. 2013; 162(4): 489–97.Maude S.L., Laetsch T.W., Buechner J., et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–48.Maude S.L., Laetsch T.W., Buechner J., et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–48.Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr. Crit. Care Med. 2015; 16: 428–39. DOI: 10.1097/PCC.0000000000000350.Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr. Crit. Care Med. 2015; 16: 428–39. DOI: 10.1097/PCC.0000000000000350.Мазуров В.И., Мартынов А.И., Жернакова Ю.В. Гиперурикемия: экспертный взгляд на проблему. Инновационная фармакотерапия. 2022; 6(10): 36–40.Mazurov V.I., Martinov A.I., Gernakova Yu.V. Hyperuricemia: expert view on the problem. Innovationnaya pfarmakoterapiya. 2022; 6(10): 36–40. (In Russian).Tambaro F.P., Wierda W.G. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020; 7(2):e168–76.Tambaro F.P., Wierda W.G. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020; 7(2):e168–76.McBride A., Trifi lio S., Baxter N., et al. Managing tumor lysis syndrome in the era of novel cancer therapies. J Adv Pract Oncol. 2017; 8(7): 705–20.McBride A., Trifi lio S., Baxter N., et al. Managing tumor lysis syndrome in the era of novel cancer therapies. J Adv Pract Oncol. 2017; 8(7): 705–20.Canet E., Zafrani L., Lambert J., et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS ONE. 2013; 8(2): e55870.Canet E., Zafrani L., Lambert J., et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS ONE. 2013; 8(2): e55870.Cómo citar: Comité Nacional de Hematología, Oncología y Medicina Transfusional. Recomendaciones para el manejo de la lisis tumoral. Arch Argent Pediatr. 2020; 118(2): S59–63.Cómo citar: Comité Nacional de Hematología, Oncología y Medicina Transfusional. Recomendaciones para el manejo de la lisis tumoral. Arch Argent Pediatr. 2020; 118(2): S59–63.Flood K., Rozmus J., Skippen P., et al. Fluid overload and acute kidney injury in children with tumor lysis syndrome. Pediatr Blood Cancer. 2021; 68(12): e29255. DOI: 10.1002/pbc.29255.Flood K., Rozmus J., Skippen P., et al. Fluid overload and acute kidney injury in children with tumor lysis syndrome. Pediatr Blood Cancer. 2021; 68(12): e29255. DOI: 10.1002/pbc.29255.Ahsan Ejaz A., Pourafshar N., Mohandas R., et al. Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS ONE. 2015; 10 (3): e0119497. DOI: 10.1371/journal.pone.0119497.Ahsan Ejaz A., Pourafshar N., Mohandas R., et al. Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS ONE. 2015; 10 (3): e0119497. DOI: 10.1371/journal.pone.0119497.Jones G.L., Will A., Jackson G.H., et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015; 169: 661–71.Jones G.L., Will A., Jackson G.H., et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015; 169: 661–71.Coiffi er B., Altman A., Pui C.H., et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26: 2767–78.Coiffi er B., Altman A., Pui C.H., et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26: 2767–78.Cheuk D.K., Chiang A.K., Chan G.C., Ha S.Y. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2017 Mar 8; 3(3): CD006945. DOI: 10.1002/14651858.CD006945.Cheuk D.K., Chiang A.K., Chan G.C., Ha S.Y. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2017 Mar 8; 3(3): CD006945. DOI: 10.1002/14651858.CD006945.Seidemann K., Meyer U., Jansen P., et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin lymphoma and B-ALL. Observations from the BFM trial. Klin Padiatr. 1998; 210: 279–84.Seidemann K., Meyer U., Jansen P., et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin lymphoma and B-ALL. Observations from the BFM trial. Klin Padiatr. 1998; 210: 279–84.Ibrahim U., Saqib A., Mohammad F., et al. Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know. J Oncol Pharm Pract. 2018; 24(4): 309–13.Ibrahim U., Saqib A., Mohammad F., et al. Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know. J Oncol Pharm Pract. 2018; 24(4): 309–13.Allen K.C., Champlain A.H., Cotliar J.A., et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2015; 38(2): 183–7.Allen K.C., Champlain A.H., Cotliar J.A., et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf. 2015; 38(2): 183–7.Сairo M.S., Thompson S., Tangirala K., Eaddy M.T. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma Myeloma Leuk. 2017; 17(3): 173–8.Сairo M.S., Thompson S., Tangirala K., Eaddy M.T. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma Myeloma Leuk. 2017; 17(3): 173–8.Relling M.V., McDonagh E.M., Chang T., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for rasburicase therapy in the context of G6PD defi ciency genotype. Clin Pharmacol Ther. 2014; 96(2): 169–74.Relling M.V., McDonagh E.M., Chang T., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for rasburicase therapy in the context of G6PD defi ciency genotype. Clin Pharmacol Ther. 2014; 96(2): 169–74.Новичкова Г.А., Птушкин В.В., Румянцев А.Г. Клинические рекомендации по профилактике и лечению синдрома лизиса опухоли у детей и подростков. Российский журнал детской гематологии и онкологии. 2014; 1: 37–50Novichkova G.A., Ptushkin V.V., Rumyantsev A.G. Clinical guidelines for the prevention and treatment of tumor lysis syndrome in children and adolescents. Rossiyskiy Gurnal Detskpy gematologii I onkologii. 2014; 1: 37–50. (In Russian).Lupușoru G., Ailincăi I., Frăţilă G. et al. Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology. Biomedicines. 2022; 10(5): 1012. DOI: 10.3390/biomedicines10051012.Lupușoru G., Ailincăi I., Frăţilă G. et al. Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology. Biomedicines. 2022; 10(5): 1012. DOI: 10.3390/biomedicines10051012.KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2: 1–138.KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2: 1–138.Tan H.K., Bellomo R., M’Pis D.A., Ronco C. Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafi ltration. Int J Artif Organs. 2001; 24(4): 186–91.Tan H.K., Bellomo R., M’Pis D.A., Ronco C. Phosphatemic control during acute renal failure: intermittent hemodialysis versus continuous hemodiafi ltration. Int J Artif Organs. 2001; 24(4): 186–91.Рей С.И., Бердников Г.А., Васина Н.В. Острое почечное повреждение 2020: эпидемиология, критерии диагностики, показания, сроки начала и модальность заместительной почечной терапии. Анестезиология и реаниматология. 2020; 5: 63–9. DOI: 10.17116/anaesthesiology202005163.Rey S.I., Berdnikov G.A., Vasina N.V. Acute kidney injury in 2020: epidemiology, diagnostic criteria, indications, timing and modality of renal replacement therapy. Anesthesiologiya I Reanimatologiya. 2020; 5: 63-9. (In Russian). DOI: 10.17116/anaesthesiology202005163.Ye Z., Wang Y., Ge L., et al. Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Crit Care Explor. 2021; 3(5): e0399. DOI: 10.1097/CCE.0000000000000399.Ye Z., Wang Y., Ge L., et al. Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Crit Care Explor. 2021; 3(5): e0399. DOI: 10.1097/CCE.0000000000000399.Gaudry S., Hajage D., Martin-Lefevre L., et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet. 2021; 397(10281): 1293–300. DOI: 10.1016/S0140-6736(21)00350-0.Gaudry S., Hajage D., Martin-Lefevre L., et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet. 2021; 397(10281): 1293–300. DOI: 10.1016/S0140-6736(21)00350-0.Zarbock A., Kellum J.A., Schmidt C., et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016; 315(20): 2190–9. DOI: 10.1001/jama.2016.5828.Zarbock A., Kellum J.A., Schmidt C., et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 2016; 315(20): 2190–9. DOI: 10.1001/jama.2016.5828.Macaluso A., Genova S., Maringhini S., et al. Acute respiratory distress syndrome associated with tumor lysis syndrome in a child with acute lymphoblastic leukemia. Pediatr Rep. 2015; 7(1): 5760. DOI: 10.4081/pr.2015.5760.Macaluso A., Genova S., Maringhini S., et al. Acute respiratory distress syndrome associated with tumor lysis syndrome in a child with acute lymphoblastic leukemia. Pediatr Rep. 2015; 7(1): 5760. DOI: 10.4081/pr.2015.5760.Pavlushkov E., Berman M., Valchanov K. Cannulation techniques for extracorporeal life support. Ann Transl Med. 2017; 5: 70. DOI: 10.21037/atm.2016.11.47.Pavlushkov E., Berman M., Valchanov K. Cannulation techniques for extracorporeal life support. Ann Transl Med. 2017; 5: 70. DOI: 10.21037/atm.2016.11.47.Lee SW, Kim YS, Hong G.J. Extracorporeal membrane oxygenation as a rescue therapy for acute respiratory failure during chemotherapy in a patient with acute myeloid leukemia. Thorac Dis. 2017; 9: 133–7. DOI: 10.21037/jtd.2017.02.23Lee SW, Kim YS, Hong G.J. Extracorporeal membrane oxygenation as a rescue therapy for acute respiratory failure during chemotherapy in a patient with acute myeloid leukemia. Thorac Dis. 2017; 9: 133–7. DOI: 10.21037/jtd.2017.02.23ELSO guidelines. Extracorporeal life support organization. https://www.elso.org/resources/guidelines.aspx 2020ELSO guidelines. Extracorporeal life support organization. https://www.elso.org/resources/guidelines.aspx 2020Wang C., Lv Z., Zhang Y. Type B lactic acidosis associated with diffuse large B-cell lymphoma and the Warburg effect. J Int Med Res. 2022; 50(1): 3000605211067749. DOI: 10.1177/03000605211067749.Wang C., Lv Z., Zhang Y. Type B lactic acidosis associated with diffuse large B-cell lymphoma and the Warburg effect. J Int Med Res. 2022; 50(1): 3000605211067749. DOI: 10.1177/03000605211067749.Ziegler C., Volkov L., Marnai R., et al. Lactic acidosis and hypoglycemia as markers of disease progression of multiple myeloma: A case report. EJHaem. 202; 2(3): 539–44. DOI: 10.1002/jha2.176.Ziegler C., Volkov L., Marnai R., et al. Lactic acidosis and hypoglycemia as markers of disease progression of multiple myeloma: A case report. EJHaem. 202; 2(3): 539–44. DOI: 10.1002/jha2.176.

The authors declare that there are no conflicts of interest present.